Resultats de la cerca - James Signorovitch
- Mostrar 1 - 20 resultats de 32
- Anar a la pàgina següent
-
1
-
2
Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis per Michael T. Nurmohamed, Yanjun Bao, James Signorovitch, Alex Trahey, Parvez Mulani, Diana Dan
Publicat 2015Artigo -
3
Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center per Jessica R. Marden, Jonathan Freimark, Zhiwen Yao, James Signorovitch, Cuixia Tian, Brenda Wong
Publicat 2020Artigo -
4
-
5
-
6
-
7
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK –Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls per Daniel Shao-Weng Tan, António Araújo, Jie Zhang, James Signorovitch, Zheng‐Yi Zhou, Xiaopeng Cai, Geoffrey Liu
Publicat 2016Artigo -
8
-
9
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States per Sunnie Kim, James Signorovitch, Hongbo Yang, Oscar Patterson‐Lomba, Cheryl Xiang, Brian Ung, Monika Parisi, John L. Marshall
Publicat 2018Artigo -
10
Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy per Francesco Muntoni, Joana Domingos, Adnan Y. Manzur, Anna Mayhew, Michela Guglieri, Gautam Sajeev, James Signorovitch, Susan J. Ward
Publicat 2019Artigo -
11
PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials per Mirko Fillbrunn, James Signorovitch, Fabrice André, Iris Wang, Inés Lorenzo, Antonia Ridolfi, Jinhee Park, Akanksha Dua, Hope S. Rugo
Publicat 2022Revisão -
12
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial per Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James Signorovitch, Vadim Romanov, Frederick L. Locke, David G. Maloney
Publicat 2020Artigo -
13
Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial per Richard T. Maziarz, Stephen J. Schuster, Vadim Romanov, Elisha S. Rusch, Junlong Li, James Signorovitch, David G. Maloney, Frederick L. Locke
Publicat 2020Artigo -
14
Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vacc... per Tianyan Hu, Yan Song, Nicolae Done, Salini Mohanty, Qing Liu, Eric Sarpong, Esteban Lemus-Wirtz, James Signorovitch, Thomas Weiß
Publicat 2023Artigo -
15
-
16
Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018 per Tianyan Hu, Nicolae Done, Tanaz Petigara, Salini Mohanty, Yan Song, Qing Liu, Esteban Lemus-Wirtz, James Signorovitch, Eric Sarpong, Thomas Weiß
Publicat 2022Artigo -
17
Linkage Disequilibrium and Inference of Ancestral Recombination in 538 Single-Nucleotide Polymorphism Clusters across the Human Genome per Andrew G. Clark, Rasmus Nielsen, James Signorovitch, Tara C. Matise, Stephen Glanowski, Jeremy Heil, Emily S. Winn-Deen, Arthur L. Holden, Eric Lai
Publicat 2003Artigo -
18
Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19 per Ankeet S. Bhatt, Karola Jering, Muthiah Vaduganathan, Brian Claggett, Jonathan W. Cunningham, Ning Rosenthal, James Signorovitch, Jens Jakob Thune, Orly Vardeny, Scott D. Solomon
Publicat 2020Artigo -
19
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment per Alexa B. Kimball, Gregor B. E. Jemec, Min Yang, Andrew Kageleiry, James Signorovitch, Martin M. Okun, Y. Gu, K. Wang, Parvez Mulani, M Sundaram
Publicat 2014Artigo -
20
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM per Lucia Masárová, Srđan Verstovšek, Tom Liu, Sumati Rao, Gautam Sajeev, Mirko Fillbrunn, Ryan Simpson, Weilong Li, Joseph Yuan‐Mou Yang, Yvette Le Lorier, Boris Gorsh, James Signorovitch
Publicat 2024Artigo
Eines de cerca:
Matèries relacionades
Medicine
Internal medicine
Pediatrics
Duchenne muscular dystrophy
Oncology
Ambulatory
Clinical trial
Biology
Confidence interval
Population
Surgery
Cancer
Environmental health
Physical therapy
Disease
Hazard ratio
Heart failure
Nursing
Pathology
Adverse effect
Alternative medicine
Cardiology
Clinical endpoint
Ejection fraction
Emergency medicine
Intensive care medicine
Muscular dystrophy
Physical medicine and rehabilitation
Proportional hazards model
Quality of life (healthcare)